Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

120%

6 of 5 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00769704Phase 3Completed

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Role: lead

NCT00402025Phase 1Completed

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Role: lead

NCT01161498Phase 3Terminated

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Role: lead

NCT00289016Phase 2Completed

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Role: lead

NCT01368276Phase 3Completed

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Role: lead

NCT02574260Phase 2Completed

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Role: lead

All 6 trials loaded